Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
02/09/2026 21:13
BRIEF-Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash Sept 2 (Reuters) - Inventiva SA IVAA.PA:
INVENTIVA ANNOUNCES LAST PATIENT VISIT IN NATIV3 PHASE 3 CLINICAL TRIAL OF LANIFIBRANOR IN MASH
INVENTIVA - REGULATORY SUBMISSION FOR LANIFIBRANOR ANTICIPATED IN H1 2027, POTENTIAL U.S. LAUNCH IN 2028
Source text: ID:nGNX3tRL24
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030